{"id":653588,"date":"2023-05-30T11:00:01","date_gmt":"2023-05-30T11:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=653588"},"modified":"2023-05-30T11:00:01","modified_gmt":"2023-05-30T11:00:01","slug":"refractory-epilepsy-market-expected-to-rise-alexza-pharmaceuticals-xenon-pharmaceuticals-gw-pharmaceuticals-equilibre-biopharmaceuticals-takeda-abide-therapeutics-otsuka-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/refractory-epilepsy-market-expected-to-rise-alexza-pharmaceuticals-xenon-pharmaceuticals-gw-pharmaceuticals-equilibre-biopharmaceuticals-takeda-abide-therapeutics-otsuka-pharmaceuticals_653588.html","title":{"rendered":"Refractory Epilepsy Market expected to rise, Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda, Abide therapeutics, Otsuka pharmaceuticals"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1685340598.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Refractory Epilepsy Market expected to rise, Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda, Abide therapeutics, Otsuka pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1685340598.jpeg\" alt=\"Refractory Epilepsy Market expected to rise, Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda, Abide therapeutics, Otsuka pharmaceuticals\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Refractory Epilepsy Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Refractory Epilepsy Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Refractory Epilepsy, historical and forecasted epidemiology as well as the Refractory Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The Refractory Epilepsy market growth is driven by factors like increase in the prevalence of Refractory Epilepsy, investments in research and development, entry of emerging therapies during the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/refractory-epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Refractory Epilepsy market report<\/a> also offers comprehensive insights into the Refractory Epilepsy market size, share, Refractory Epilepsy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Refractory Epilepsy market size growth forward.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights from the Refractory Epilepsy Market Insights Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Several key pharmaceutical companies, including Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A\/S, Spark Therapeutics,&nbsp; Equilibre Biopharmaceuticals,&nbsp; ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research &amp; Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics,&nbsp; Cerebral Therapeutics, Engrail Therapeutics, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.&nbsp;<\/li>\n<li>The total Refractory Epilepsy market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.<\/li>\n<li>As per DelveInsight analysis, the Refractory Epilepsy market is anticipated to witness growth at a considerable CAGR<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Strategise your business goals by understanding market dynamics @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/refractory-epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Refractory Epilepsy Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Refractory Epilepsy Overview&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">Refractory epilepsy occurs when your anti-epilepsy medicines are no longer controlling your seizures. Often the cause of refractory epilepsy is not known. Your healthcare provider will likely give you other medicines to try to get your seizures under control.<\/p>\n<p style=\"text-align: justify;\"><strong>Do you know the treatment paradigms for different countries? Download our <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/refractory-epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Refractory Epilepsy Market Sample Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Refractory Epilepsy Epidemiology Segmentation&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Refractory Epilepsy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Refractory Epilepsy historical patient pools and forecasted Refractory Epilepsy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Refractory Epilepsy Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Refractory Epilepsy Prevalence&nbsp;<\/li>\n<li>Age-Specific Refractory Epilepsy Prevalence&nbsp;<\/li>\n<li>Gender-Specific Refractory Epilepsy Prevalence&nbsp;<\/li>\n<li>Diagnosed and Treatable Cases of Refractory Epilepsy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Visit for more @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/refractory-epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Refractory Epilepsy Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Refractory Epilepsy Treatment Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The Refractory Epilepsy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Refractory Epilepsy market trends by analyzing the impact of current Refractory Epilepsy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\">This segment gives a thorough detail of Refractory Epilepsy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria&#8217;s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Refractory Epilepsy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\">According to DelveInsight, the Refractory Epilepsy market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Refractory Epilepsy Emerging Therapies and Key Companies:<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<colgroup>\n<col width=\"142\" \/>\n<col width=\"356\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p><strong>Refractory Epilepsy Therapies<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Key Refractory Epilepsy Companies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>Alprazolam inhalation&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Engage Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>XEN1101<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Xenon Pharmaceuticals<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>TAK-935<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Takeda Pharmaceuticals<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>Cannabidivarin<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>GW Pharmaceuticals<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>EQU-001<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Equilibre Biopharmaceuticals<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>OPC 214870<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Otsuka Pharmaceutical Development &amp; Commercialization<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>AVCN-319302<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Avicanna<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>For more information, visit <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/refractory-epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Refractory Epilepsy Market Analysis, Patient Pool, and Emerging Therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Refractory Epilepsy Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>11 Years Forecast<\/li>\n<li>7MM Coverage&nbsp;<\/li>\n<li>Descriptive overview of Refractory Epilepsy, causes, signs and symptoms, diagnosis, treatment<\/li>\n<li>Comprehensive insight into Refractory Epilepsy epidemiology in the 7MM<\/li>\n<li>Refractory Epilepsy marketed and emerging therapies&nbsp;<\/li>\n<li>Refractory Epilepsy companies<\/li>\n<li>Refractory Epilepsy market drivers and barriers&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key Questions Answered in the Refractory Epilepsy Market Report 2032:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What was the Refractory Epilepsy market share distribution in 2019, and how would it appear in 2032?<\/li>\n<li>What is the total Refractory Epilepsy market size and the market size by therapy across the 7MM for the study period (2019-32)?<\/li>\n<li>What are the important findings from 7MM, and which country will have the greatest Refractory Epilepsy market size from 2019-32?<\/li>\n<li>During the study period (2019-2032), at what CAGR is the Refractory Epilepsy market projected to expand at 7MM?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Refractory Epilepsy Market Key Comprehensive Insights&nbsp;<\/p>\n<p style=\"text-align: justify;\">2 Refractory Epilepsy Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">3 Competitive Intelligence Analysis for Refractory Epilepsy<\/p>\n<p style=\"text-align: justify;\">4 Refractory Epilepsy Market Analysis Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5 Executive Summary of Refractory Epilepsy<\/p>\n<p style=\"text-align: justify;\">6 Refractory Epilepsy Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">7 Refractory Epilepsy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8 Refractory Epilepsy Patient Journey<\/p>\n<p style=\"text-align: justify;\">9 Refractory Epilepsy Treatment Algorithm, Refractory Epilepsy Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10 Key Endpoints in Refractory Epilepsy Clinical Trials<\/p>\n<p style=\"text-align: justify;\">11 Refractory Epilepsy Marketed Therapies&nbsp;<\/p>\n<p style=\"text-align: justify;\">12 Refractory Epilepsy Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13 Refractory Epilepsy: 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14 Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15 Access and Reimbursement Overview of Refractory Epilepsy<\/p>\n<p style=\"text-align: justify;\">16 Refractory Epilepsy Market Key Opinion Leaders Reviews<\/p>\n<p style=\"text-align: justify;\">18 Refractory Epilepsy Market Drivers<\/p>\n<p style=\"text-align: justify;\">19 Refractory Epilepsy Market Barriers<\/p>\n<p style=\"text-align: justify;\">20 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">21 Disclaimer<\/p>\n<p style=\"text-align: justify;\">22 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">23 About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Refractory Epilepsy Epidemiology 2032<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;Refractory Epilepsy &#8211; Epidemiology Forecast to 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted Refractory Epilepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Refractory Epilepsy Pipeline 2023<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Refractory Epilepsy Pipeline Insights, 2023&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Refractory Epilepsy market. A detailed picture of the Refractory Epilepsy pipeline landscape is provided, which includes the disease overview and Refractory Epilepsy treatment guidelines.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=refractory-epilepsy-market-expected-to-rise-alexza-pharmaceuticals-xenon-pharmaceuticals-gw-pharmaceuticals-equilibre-biopharmaceuticals-takeda-abide-therapeutics-otsuka-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=refractory-epilepsy-market-expected-to-rise-alexza-pharmaceuticals-xenon-pharmaceuticals-gw-pharmaceuticals-equilibre-biopharmaceuticals-takeda-abide-therapeutics-otsuka-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Refractory Epilepsy Market DelveInsight&#8217;s &#8220;Refractory Epilepsy Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Refractory Epilepsy, historical and forecasted epidemiology as well as the Refractory Epilepsy market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/refractory-epilepsy-market-expected-to-rise-alexza-pharmaceuticals-xenon-pharmaceuticals-gw-pharmaceuticals-equilibre-biopharmaceuticals-takeda-abide-therapeutics-otsuka-pharmaceuticals_653588.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-653588","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=653588"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653588\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=653588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=653588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=653588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}